Cytoreg® demonstrates high efficacy in B16F1 Melanoma Cancer

Dec. 19, 2012 - PRLog -- December 15, 2012.

Cytorex de Venezuela S.A., a subsidiary of Cytorex Biosciences Inc. (http://www.cytorex.com) a biotechnology company located in South Florida (USA), announced today a research report entitled “Effectiveness of test agent Cytoreg ® on B16F1 melanoma cells inoculated in female mice”.

This report is part of the research and development agreement established between Cytorex and  the Vivarium of the University of Los Andes (ULA) in Merida, Venezuela,.  The research results presentation of the study was conducted by university student researchers, and was held at the premises of the Faculty of Science at ULA.

The results demonstrated the high effectiveness of Cytoreg®, an ionic therapeutic agent, in reducing the B16F1 melanoma tumors, and in inhibiting metastasis in animals that were included in the experimental  “In Vivo” model.

Results obtained in this study allowed to show that female mice C57BL/6//BIOU carriers of  the tumor, and which were treated with Cytoreg®, had a significant decrease of tumor size when compared with the female mice in the control  group that received no treatment.

Cytoreg®’s  efficacy was compared with Interferon Alpha, a cytokine that is used as first-line treatment of patients with melanoma, resulting in Cytoreg® being more effective in reducing tumors.

The results of three complementary protocols, which describe the effectiveness of B16F1 Melanoma tumor reduction by Cytoreg®, were also presented. These studies were related to: 1) hematologic evaluation, 2) organ toxicity and 3) pathological analysis of B16F1 melanoma tumors after treatment with Cytoreg®.

Assay data showed no toxicity, and no presence of side effects caused by Cytoreg®. This was evidenced by measuring the motor capacity, weight gain and feed intake in grams/day for the animals during the test period. These results were also compared with the results obtained by the use of interferon alpha, which is the conventional treatment of melanoma, resulting Cytoreg® with a) no toxicity, b) with greater effectiveness in stimulating the immune system, and c) with a high percentage of suppression of vascularization of  tumors versus Interferon Alfa. Of all the proven mechanisms of action and Cytoreg ® certified so far, one is its high capacity of antiangiogenesis (prevents tumor vascularization).

Cytoreg ® is a novel chemical technology invention, which is defined as a therapeutic ionic agent (nano-particles) derived from a perfectly balanced mixture of strong and weak acids (ion balance), forming a complex of ionic transport (electrons) in high concentrations in the cells that triggers multiple mechanisms of action that can regulate mitochondrial and cell metabolism, and the selective removal of neoplastic cells. Currently Cytoreg® is in the stage of preclinical development, for further accreditation with Health Agencies in Latin America and USFDA.

William Jimenez, CEO of Cytorex Venezuela S.A.,   and Vice-President  & Director of Cytorex Biosciences Inc. emphasized that these results presented at the Scientific Assessment Panel of the Faculty of Science at ULA will be published in the first quarter of 2013.

For more information please contact in Venezuela, Mr. William Jimenez,  VP  at: +58 414 614-0226, or in the United States, Mr. Carlos M. Garcia, COO  at: +1 954-573-4006.